Alkermes 경영진
경영진 기준 점검 4/4
Alkermes CEO는 Richard Pops, Sep2011 에 임명되었습니다 의 임기는 14.67 년입니다. 총 연간 보상은 $7.92M, 15.8% 급여 및 84.2% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $48.21M 가치에 해당하는 회사 주식의 0.83% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.9 년과 6.7 년입니다.
핵심 정보
Richard Pops
최고경영자
US$7.9m
총 보수
| CEO 급여 비율 | 15.80% |
| CEO 재임 기간 | 14.7yrs |
| CEO 지분 보유율 | 0.8% |
| 경영진 평균 재임 기간 | 5.9yrs |
| 이사회 평균 재임 기간 | 6.7yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 01
ALKS: Sleep And Narcolepsy Franchise Will Drive Future Upside Potential
Analysts have nudged Alkermes' fair value estimate slightly higher to about $57.33, reflecting updated assumptions for revenue growth, stronger margins and a lower future P/E that are echoed in recent price target revisions and commentary around the company's sleep and narcolepsy franchises. Analyst Commentary Recent research on Alkermes points to a mixed but generally constructive backdrop, with several bullish analysts emphasizing the potential of the sleep and narcolepsy portfolio and its impact on valuation assumptions.
내러티브 업데이트 • Apr 16
ALKS: Sleep Franchise And Orexin Program Will Shape Future Upside Potential
Narrative Update: Alkermes Analyst Price Target Shift The updated analyst price target for Alkermes moves modestly higher by about $0.53, as analysts factor in revised assumptions around revenue growth, profit margins, and a higher future P/E, tied in part to the evolving sleep and narcolepsy franchise following recent research updates. Analyst Commentary Recent research on Alkermes reflects a mix of optimism around the sleep and narcolepsy portfolio and caution on execution, pricing assumptions, and the performance of legacy products.내러티브 업데이트 • Apr 01
ALKS: Sleep Franchise And Orexin Pipeline Will Drive Future Upside
Analysts made a small upward adjustment in the price target for Alkermes to about $43.71, supported by refreshed models around the company's emerging sleep and narcolepsy franchise, recent M&A activity in the biotech space, and updated views on future P/E multiples and profitability. Analyst Commentary Recent Street research on Alkermes circles around how the emerging sleep and narcolepsy franchise, the Avadel acquisition, and updated pricing assumptions could feed into growth expectations, while also flagging execution and valuation risks.
내러티브 업데이트 • Mar 18
ALKS: Sleep Franchise And Orexin Breakthrough Will Drive Future Upside Potential
Narrative Update The updated analyst price target for Alkermes moves to $31.30 from $30.00, as analysts factor in revised revenue growth assumptions tied to the expanding sleep and narcolepsy franchise and the completed Avadel acquisition, along with adjusted views on profit margins and future P/E. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with analysts weighing the potential of the sleep and narcolepsy franchise against execution and valuation questions.내러티브 업데이트 • Mar 04
ALKS: Emerging Sleep Franchise And Orexin Program Will Drive Future Upside
Narrative Update on Alkermes The updated analyst price target for Alkermes edges down from $43.75 to about $43.65, as analysts balance slightly higher modeled revenue growth with lower profit margin assumptions and a higher future P/E tied to the growing sleep and narcolepsy franchise, including Lumryz and the orexin program. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with some analysts leaning constructive on the emerging sleep and narcolepsy portfolio and others more restrained on valuation and execution risk.내러티브 업데이트 • Feb 18
ALKS: Improved CVR Offer Terms Will Support Future Sleep Disorder Leadership
Analysts have slightly lowered their price target on Alkermes to $43.75 from $43.81, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E after reviewing the company's revised offer terms highlighted in recent Street research. Analyst Commentary Recent Street research around Alkermes is centered on the revised offer terms, especially the contingent value right, or CVR, structure that sits alongside the upfront consideration.내러티브 업데이트 • Feb 04
ALKS: Avadel Bid And Orexin Breakthrough Status Will Support Future Sleep Leadership
Analysts kept their Alkermes fair value estimate steady at about $43.81 per share while nudging up projected revenue growth and future P/E assumptions and trimming profit margin expectations, reflecting mixed reactions to the latest narcolepsy data and the evolving Avadel bid. Analyst Commentary Street research around Alkermes focuses on the mixed narcolepsy data, the competitive orexin pipeline, and the evolving Avadel bid, with investors weighing both upside optionality and execution risks.내러티브 업데이트 • Jan 20
ALKS: Avadel Sleep Deal And Orexin Breakthrough Designation Will Drive Upside
Analysts have trimmed their Alkermes price target by a small amount to reflect a slightly higher discount rate and somewhat lower expected profit margin, while still factoring in stronger modeled revenue growth and updated views on the Avadel acquisition and alixorexton sleep pipeline data. Analyst Commentary Bullish analysts are generally framing the recent updates around Alkermes as a mixed but constructive setup, with the Avadel acquisition and alixorexton data keeping the stock firmly on institutional radar.Seeking Alpha • Jan 09
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
Summary Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS’s robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton’s Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline. The Avadel deal provides immediate revenue, a seasoned sales force, and reduces commercial launch risk for alixorexton, despite integration and financial risks. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 06
ALKS: Sleep Franchise Acquisition Will Drive Future Orexin Class Leadership
Analysts have trimmed their Alkermes fair value estimate by about $0.06 per share to $43.81 as they weigh mixed alixorexton data against generally positive views on the Avadel acquisition and Alkermes' role in the emerging orexin class. Analyst Commentary Street research around Alkermes and its sleep portfolio is split between enthusiasm for the Avadel acquisition and orexin opportunity, and caution around alixorexton data quality and competitive pressures.내러티브 업데이트 • Dec 20
ALKS: Avadel Deal And Sleep Franchise Are Poised To Drive Upside
The analyst price target for Alkermes has been raised by about $4 to approximately $57 per share, as analysts factor in stronger expected revenue growth and profit margins supported by the strategic Avadel acquisition and resilient alixorexton sleep-disorder franchise prospects. Analyst Commentary Bullish analysts emphasize that the Avadel transaction, combined with a clearer outlook for alixorexton in narcolepsy and hypersomnia, materially improves Alkermes' growth, margin, and capital allocation story.내러티브 업데이트 • Dec 06
ALKS: Sleep Medicine Acquisition Will Drive Future Orexin Opportunity Upside
Analysts modestly lift their price target on Alkermes, reflecting confidence that the strategically priced Avadel acquisition, solid narcolepsy data and an underappreciated orexin class opportunity can drive upside, despite only incremental changes to long term growth and profitability assumptions. Analyst Commentary Street views on Alkermes remain mixed, with a generally constructive stance on long term positioning in sleep medicine and orexin agonists, tempered by questions around differentiation, safety profile and competitive intensity.내러티브 업데이트 • Nov 21
ALKS: Sleep Medicine Acquisition Will Drive Momentum After Narcolepsy Study Results
Analysts have slightly reduced their price target for Alkermes to $43.88 from $44, reflecting tempered revenue growth assumptions and competitive data from recent narcolepsy studies. Analyst Commentary Analyst sentiment regarding Alkermes remains divided following the latest developments in its narcolepsy franchise and pending acquisition of Avadel Pharmaceuticals.내러티브 업데이트 • Nov 06
ALKS: Clinical Progress In Narcolepsy Will Drive Share Momentum This Fall
Analysts have raised their fair value estimate for Alkermes from $42.53 to $44.00 per share. They cite stronger revenue growth forecasts and recent clinical and strategic updates, which improve the company's near- and mid-term outlook.분석 기사 • Oct 31
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next
As you might know, Alkermes plc ( NASDAQ:ALKS ) just kicked off its latest third-quarter results with some very strong...내러티브 업데이트 • Oct 22
Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation
Alkermes' analyst price target was raised approximately $0.95 to $42.53 per share, as analysts point to improved profit margin outlook and the anticipated benefits from its Avadel Pharmaceuticals acquisition. These factors are expected to support both near- and mid-term growth.분석 기사 • May 31
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alkermes fair value estimate is US$59.40 Current share price...Seeking Alpha • Feb 25
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Summary Recently, Alkermes refocused on neuroscience, and now it’s dealing with stabilizing revenues from core products like Lybalvi, Vivitrol, Aristada, and Vumerity. However, the main growth driver going forward will be ALKS 2680. This is a once-daily oral OX2R agonist for narcolepsy treatment. ALKS is also now debt‑free with strong cash reserves and positive cash flow. So, it should be able to self fund its new bet on ALKS 2680. Their key Phase 2 trials are currently with Vibrance‑1 and Vibrance‑2, which could give us a clearer picture of ALKS 2680’s true potential. I accept ALKS trades at a slight premium relative to its peers, but it has robust financials and great cash flow to bet on ALKS 2680. So, I reiterate my “Buy” on ALKS stock. Read the full article on Seeking AlphaSeeking Alpha • Nov 24
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Summary Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectively fund R&D and operations. Risks include potential clinical trial failures for ALKS 2680 and competitive pressures in the CNS market, but long-term prospects remain favorable. Despite trading near fair value, ALKS's robust financials and positive cash flow support its R&D and potential future growth, making it a viable "buy on dips" stock. Read the full article on Seeking Alpha
새 내러티브 • Aug 31
Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges
Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.Seeking Alpha • Jul 28
Alkermes: Fairly Valued After Post-Earnings Bump
Summary Today, we take a look at Alkermes plc, a mid-cap biopharma company headquartered in Dublin, Ireland. The company has several products on the market and the stock has moved up 15% in the past two weeks, thanks to sector rotation and solid Q2 results. Management has done a solid job in recent quarters streamlining the company, and Alkermes also has a significant stock buyback program. The shares still trade under 11 times forward earnings. Still more upside ahead? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 17
The Bottom Fishing Club: Alkermes Has Great Value And Safety
Summary Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and neurological disorders like narcolepsy. Alkermes has a very low valuation compared to peers in the pharmaceutical industry, making it an interesting pick to add defensive characteristics to your portfolio. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Summary Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this year. Q4 earnings show robust revenue growth, led by Lybalvi, which significantly outpaced other products with 61% year-over-year growth. Financially healthy, Alkermes has a strong balance sheet, positive cash flow, and anticipates growth in revenue and net income for 2024. I am maintaining my "Buy" rating based on Q4 earnings, ALKS-2680's potential in a growing narcolepsy market, despite risks from generic competition and market sentiment. Read the full article on Seeking AlphaSeeking Alpha • Jan 26
Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Summary Alkermes plc, a neuroscience company, has undergone restructuring and simplification, including spinning out its oncology business and selling its manufacturing facility. Despite a turbulent year, Alkermes' stock price remains relatively stable, but the company has not recorded a net profit in recent years. Alkermes' product portfolio includes Vivitrol, Aristada, and Lybalvi, with positive revenue growth, but the company will need to diversify to offset declining sales of Vivitrol. A narcolepsy drug candidate intrigues, given its "blockbuster" revenue potential, although Avadel Pharma's recent approval for Lumryz clouds the outlook. All things considered, while Alkermes has solved some major problems in 2023, I would assign the company a "Hold" recommendation in 2024 due to a lack of compelling growth catalysts. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$153m |
| Dec 31 2025 | US$8m | US$1m | US$242m |
| Sep 30 2025 | n/a | n/a | US$338m |
| Jun 30 2025 | n/a | n/a | US$348m |
| Mar 31 2025 | n/a | n/a | US$356m |
| Dec 31 2024 | US$10m | US$1m | US$372m |
| Sep 30 2024 | n/a | n/a | US$387m |
| Jun 30 2024 | n/a | n/a | US$386m |
| Mar 31 2024 | n/a | n/a | US$570m |
| Dec 31 2023 | US$9m | US$1m | US$519m |
| Sep 30 2023 | n/a | n/a | US$455m |
| Jun 30 2023 | n/a | n/a | US$300m |
| Mar 31 2023 | n/a | n/a | -US$9m |
| Dec 31 2022 | US$10m | US$1m | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$129m |
| Jun 30 2022 | n/a | n/a | -US$94m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$9m | US$1m | US$76m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$8m | US$1m | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$74m |
| Jun 30 2020 | n/a | n/a | -US$126m |
| Mar 31 2020 | n/a | n/a | -US$139m |
| Dec 31 2019 | US$15m | US$1m | -US$197m |
보상 대 시장: Richard의 총 보수(USD7.92M)는 US 시장에서 비슷한 규모 기업의 평균(USD8.41M) 수준입니다.
보상과 수익: Richard의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Richard Pops (63 yo)
14.7yrs
재임 기간
US$7,915,081
보수
Mr. Richard F. Pops has been the Chief Executive Officer and Director of Alkermes PLC since September 2011 and its Chairman since September 16, 2011. Mr. Pops was the Founder of Genomics Collaborative, Inc...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & CEO | 14.7yrs | US$7.92m | 0.83% $ 48.2m | |
| Senior VP & CFO | less than a year | US$4.23m | 데이터 없음 | |
| Executive VP | 5.3yrs | US$4.03m | 0.14% $ 8.4m | |
| Executive VP | 10yrs | US$3.47m | 0.14% $ 8.1m | |
| Executive VP of Research & Development and Chief Medical Officer | 9yrs | US$3.62m | 0.049% $ 2.8m | |
| Senior VP & Chief Commercial Officer | 6yrs | US$2.79m | 0.066% $ 3.8m | |
| Interim Principal Accounting Officer & VP of Finance | 2.3yrs | 데이터 없음 | 0.0046% $ 270.0k | |
| SVP & Chief Information Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Affairs & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Human Resources Officer | 5.9yrs | 데이터 없음 | 데이터 없음 | |
| SVP of Policy | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Operations and Environment | no data | 데이터 없음 | 데이터 없음 |
5.9yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: ALKS의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.9 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & CEO | 14.7yrs | US$7.92m | 0.83% $ 48.2m | |
| Independent Director | 5.4yrs | US$491.33k | 0.026% $ 1.5m | |
| Independent Director | 10yrs | US$479.14k | 0.019% $ 1.1m | |
| Independent Director | 2.2yrs | US$476.21k | 0.0081% $ 474.1k | |
| Independent Director | 8.2yrs | US$484.75k | 0.062% $ 3.6m | |
| Independent Director | 4.5yrs | US$461.01k | 0.017% $ 1.0m | |
| Lead Independent Director | 6.7yrs | US$527.23k | 0.019% $ 1.1m | |
| Independent Director | 4yrs | US$477.84k | 0.014% $ 805.4k | |
| Independent Director | 6.7yrs | US$474.01k | 0.019% $ 1.1m |
6.7yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: ALKS의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.7 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 09:02 |
| 종가 | 2026/05/11 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Alkermes plc는 34명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |